生物制剂与合成改善病情抗风湿药治疗类风湿关节炎的心血管事件比较风险:系统评价与荟萃分析
该系统评价与荟萃分析纳入14项观察性研究,比较肿瘤坏死因子抑制剂(TNFi)、非TNFi生物制剂和传统合成改善病情抗风湿药(csDMARDs)在类风湿关节炎(RA)患者中的心血管风险。与TNFi相比,托珠单抗可能与主要不良心血管事件(MACE)风险降低相关,而csDMARDs可能与MACE和卒中风险增加相关。
要点
- 与TNFi相比,托珠单抗与MACE风险降低相关(OR 0.59)。
- 与TNFi相比,csDMARDs与MACE风险增加相关(OR 1.45-2.57)。
- 与TNFi相比,csDMARDs与卒中风险增加相关(OR 1.17)。
核心结论
- 基于荟萃分析,与TNFi相比,托珠单抗可能与MACE风险降低相关,而csDMARDs可能与MACE和卒中风险增加相关。
研究设计与样本
- 系统检索截至2018年5月8日,纳入14项观察性研究,对象为接受TNFi、非TNFi生物制剂、托法替布或csDMARDs治疗的成人RA患者,仅纳入报告活性对照的研究。
主要发现
- 与TNFi相比,托珠单抗与MACE风险降低相关(OR 0.59 [95% CI 0.34-1.00])。
- 与TNFi相比,csDMARDs(包括甲氨蝶呤)与MACE风险增加相关(OR 1.45 [95% CI 1.09-1.93]),不含甲氨蝶呤的csDMARDs OR 2.57 [95% CI 1.32-5.00],无异质性(I2 = 0%)。
- 阿巴西普与TNFi之间(OR 0.89 [95% CI 0.71-1.11])、托珠单抗与阿巴西普之间(OR 0.81 [0.57-1.16])MACE风险无差异。
- 基于11个队列(n = 135,053例患者),与TNFi相比,csDMARDs与卒中风险增加相关(OR 1.17 [95% CI 1.01-1.36]);不同生物制剂间卒中风险无差异(托珠单抗 vs TNFi OR 0.98 [95% CI 0.59-1.61];阿巴西普 vs TNFi OR 1.08 [0.86-1.34];托珠单抗 vs 阿巴西普 OR 0.73 [95% CI 0.39-1.38]),无异质性(I2 = 0%)。
- 未发现托法替布心血管风险的比较研究。
关键数值与推荐
- 与TNFi相比,托珠单抗的MACE OR 0.59(95% CI 0.34-1.00)。
- 与TNFi相比,csDMARDs(包括甲氨蝶呤)的MACE OR 1.45(95% CI 1.09-1.93),不含甲氨蝶呤的csDMARDs OR 2.57(95% CI 1.32-5.00)。
- 与TNFi相比,csDMARDs的卒中OR 1.17(95% CI 1.01-1.36)。
临床怎么用
- 在RA患者选择改善病情抗风湿药时,可考虑不同药物对心血管风险的可能影响,尤其对已有心血管风险的患者。
- 托珠单抗可能相对于TNFi具有更低的MACE风险,而csDMARDs可能增加MACE和卒中风险。
局限性
- 纳入研究均为观察性研究,可能存在混杂偏倚。
- 未发现托法替布心血管风险的比较研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We performed a systematic review and meta-analysis to evaluate the comparative effects of tumor necrosis factor inhibitors (TNFi), non-TNFi biologics, and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on cardiovascular risk in rheumatoid arthritis (RA). METHODS: Using a systematic search through May 8, 2018, we included 14 observational studies in adults with RA treated with TNFi, non-TNFi biologics, tofacitinib, or csDMARDs, reporting the risk of major adverse cardiovascular events (MACE) or stroke. Only studies reporting active comparators were included. We performed random effects meta-analysis and estimated odds ratios (ORs) and 95% confidence intervals (95% CIs). RESULTS: As compared to TNFi, tocilizumab was associated with a decreased risk of MACE (OR 0.59 [95% CI 0.34-1.00]), whereas csDMARDs were associated with an increased risk of MACE (csDMARDs including methotrexate OR 1.45 [95% CI 1.09-1.93]; without methotrexate OR 2.57 [95% CI 1.32-5.00]), without heterogeneity (I2 = 0%); there was no difference in risk of MACE between abatacept and TNFi (OR 0.89 [95% CI 0.71-1.11]), or between tocilizumab and abatacept (OR 0.81 [0.57-1.16]). Based on 11 cohorts (n = 135,053 patients), as compared to TNFi, csDMARDs were associated with an increased risk of stroke (OR 1.17 [95% CI 1.01-1.36]); there was no difference in risk of stroke between different biologics (tocilizumab versus TNFi OR 0.98 [95% CI 0.59-1.61]; abatacept versus TNFi OR 1.08 [0.86-1.34]; tocilizumab versus abatacept OR 0.73 [95% CI 0.39-1.38]), without heterogeneity (I2 = 0%). No comparative studies on cardiovascular risk with tofacitinib were identified. CONCLUSION: Based on meta-analysis, as compared to TNFi, tocilizumab may be associated with a reduced risk of MACE, whereas csDMARDs may be associated with an increased risk of MACE and stroke.
引用
- Singh S, Fumery M, Singh AG, et al. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020. PMID: 30875456. doi:10.1002/acr.23875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。